Bayer Korea Divests OTC Oral Contraceptives To Gain Merck’s Market-Leading Brand
This article was originally published in The Tan Sheet
Executive Summary
In the first move by a South Korean pharma to acquire global brand drugs, Dong-A Pharm takes over four oral contraceptive products from Bayer Korea to beef up its OTC business and female product portfolios. Bayer Korea, meanwhile, turns its acquisition sights on MSD Korea’s market-leading Mercilon.
You may also be interested in...
Lonely At The Top? Not In OTC Sector As Bayer, GSK/Novartis Challenge J&J
Bayer closes its acquisition of Merck & Co.’s consumer business, aiming to become the top OTC player and saying other consumer product acquisitions could follow. Glaxo and Novartis look to close their agreement to combine their OTC businesses in the first half of 2015.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.
Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative
South Korea is moving forward with plan to set up a Boston-type biotech cluster in Osong as part of a broader initiative unveiled by President Yoon, while the biopharma industry is calling for rapid process, exceptional support.